JP5943998B2 - 嗜癖の処置のための化合物 - Google Patents

嗜癖の処置のための化合物 Download PDF

Info

Publication number
JP5943998B2
JP5943998B2 JP2014519122A JP2014519122A JP5943998B2 JP 5943998 B2 JP5943998 B2 JP 5943998B2 JP 2014519122 A JP2014519122 A JP 2014519122A JP 2014519122 A JP2014519122 A JP 2014519122A JP 5943998 B2 JP5943998 B2 JP 5943998B2
Authority
JP
Japan
Prior art keywords
compound
stereoisomers
pharmaceutically acceptable
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014519122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520809A (ja
JP2014520809A5 (enExample
Inventor
カリーナ イー． カニッツァーロ，
カリーナ イー． カニッツァーロ，
ミカエル グラウプ，
ミカエル グラウプ，
フアン エー． ゲレロ，
フアン エー． ゲレロ，
ヤファン リュ，
ヤファン リュ，
ロバート ジー． ストリックリー，
ロバート ジー． ストリックリー，
チャンドラセカール ベンカタラマニ，
チャンドラセカール ベンカタラマニ，
ジェフ ザブロッキ，
ジェフ ザブロッキ，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド, ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2014520809A publication Critical patent/JP2014520809A/ja
Publication of JP2014520809A5 publication Critical patent/JP2014520809A5/ja
Application granted granted Critical
Publication of JP5943998B2 publication Critical patent/JP5943998B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014519122A 2011-07-01 2012-06-29 嗜癖の処置のための化合物 Expired - Fee Related JP5943998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161503923P 2011-07-01 2011-07-01
US61/503,923 2011-07-01
PCT/US2012/044809 WO2013006400A1 (en) 2011-07-01 2012-06-29 Compounds for the treatment of addiction

Publications (3)

Publication Number Publication Date
JP2014520809A JP2014520809A (ja) 2014-08-25
JP2014520809A5 JP2014520809A5 (enExample) 2015-07-23
JP5943998B2 true JP5943998B2 (ja) 2016-07-05

Family

ID=46513858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014519122A Expired - Fee Related JP5943998B2 (ja) 2011-07-01 2012-06-29 嗜癖の処置のための化合物

Country Status (32)

Country Link
US (6) US8558001B2 (enExample)
EP (2) EP2993170B1 (enExample)
JP (1) JP5943998B2 (enExample)
KR (2) KR101664915B1 (enExample)
CN (1) CN103635460B (enExample)
AP (1) AP3544A (enExample)
AR (1) AR086792A1 (enExample)
AU (1) AU2012279332B2 (enExample)
BR (1) BR112014000033A2 (enExample)
CA (1) CA2840763C (enExample)
CL (1) CL2013003597A1 (enExample)
CO (1) CO6821964A2 (enExample)
CR (1) CR20130659A (enExample)
DK (1) DK2993170T3 (enExample)
EA (1) EA025573B1 (enExample)
EC (1) ECSP13013087A (enExample)
ES (2) ES2553829T3 (enExample)
IL (1) IL230657B (enExample)
MA (1) MA35404B1 (enExample)
MD (1) MD4436B1 (enExample)
MX (1) MX337611B (enExample)
PE (1) PE20141067A1 (enExample)
PH (1) PH12013502674A1 (enExample)
PL (1) PL2726460T3 (enExample)
PT (1) PT2726460E (enExample)
SG (1) SG10201605355RA (enExample)
SI (1) SI2726460T1 (enExample)
TW (1) TWI567061B (enExample)
UA (1) UA109199C2 (enExample)
UY (1) UY34165A (enExample)
WO (1) WO2013006400A1 (enExample)
ZA (1) ZA201308977B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (enExample) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
KR20150135332A (ko) * 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
SG11201604477SA (en) * 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
US10077669B2 (en) 2014-11-26 2018-09-18 United Technologies Corporation Non-metallic engine case inlet compression seal for a gas turbine engine
US10289971B2 (en) 2015-02-13 2019-05-14 Atlassian Pty Ltd Issue and trigger rebalancing in a ranked issue management system
AU2017313390A1 (en) 2016-08-19 2019-03-07 The University Of Bristol Cytisine derivatives for the treatment of addiction
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019079209A1 (en) * 2017-10-16 2019-04-25 Amygdala Neurosciences, Inc. POLYTHERAPY FOR THE PREVENTION OF AN ADDICTION
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
JP6899975B2 (ja) 2018-05-14 2021-07-07 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ−１阻害剤
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
EP3829562A1 (en) * 2018-07-27 2021-06-09 Amygdala Neurosciences, Inc. Combination therapy for nicotine addiction
EP3863424A4 (en) * 2018-10-12 2022-08-03 Amygdala Neurosciences, Inc. ADDICTION TREATMENT OF AN ALCOHOLIC PATIENT POPULATION
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
EP4540228A1 (en) 2022-06-14 2025-04-23 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
JP2025520426A (ja) 2022-06-14 2025-07-03 アミグダラ ニューロサイエンシーズ， インコーポレイテッド Ａｌｄｈ－２阻害化合物及び使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5204369A (en) 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
AU3899199A (en) 1998-05-12 1999-11-29 Endowment for Research in Human Biology, Inc., The Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
MXPA05000122A (es) * 2002-06-27 2005-12-14 Endowment For Res In Human Bio Compuestos utiles para la inhibicion de aldehido-deshidrogenasa.
JP2004182657A (ja) * 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
RU2008151762A (ru) * 2006-07-27 2010-06-27 Си Ви Терапьютикс, Инк. (Us) Adlh-2 ингибиторы для лечения аддикции
US20080207610A1 (en) 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
US8158810B2 (en) 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
JP2011510072A (ja) 2008-01-24 2011-03-31 ギリアード・パロ・アルト・インコーポレイテッド 嗜癖の処置におけるａｌｄｈ−２インヒビター
KR20110002492A (ko) 2008-05-01 2011-01-07 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP2012506856A (ja) * 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
TWI567061B (zh) * 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物

Also Published As

Publication number Publication date
US9610299B2 (en) 2017-04-04
CA2840763C (en) 2019-09-10
CO6821964A2 (es) 2013-12-31
US20170266210A1 (en) 2017-09-21
US8575353B2 (en) 2013-11-05
CL2013003597A1 (es) 2014-06-13
WO2013006400A1 (en) 2013-01-10
EA201391635A1 (ru) 2014-04-30
US8558001B2 (en) 2013-10-15
BR112014000033A2 (pt) 2019-06-18
US20180338989A1 (en) 2018-11-29
AR086792A1 (es) 2014-01-22
US9987295B2 (en) 2018-06-05
AU2012279332A1 (en) 2013-04-04
DK2993170T3 (da) 2018-01-29
US20140051668A1 (en) 2014-02-20
HK1217487A1 (en) 2017-01-13
JP2014520809A (ja) 2014-08-25
EA025573B1 (ru) 2017-01-30
EP2993170A1 (en) 2016-03-09
KR101664915B1 (ko) 2016-10-11
UA109199C2 (uk) 2015-07-27
PH12013502674A1 (en) 2014-02-10
US20150250805A1 (en) 2015-09-10
CN103635460B (zh) 2016-03-16
CN103635460A (zh) 2014-03-12
MX337611B (es) 2016-03-10
AP3544A (en) 2016-01-14
MA35404B1 (fr) 2014-09-01
UY34165A (es) 2013-01-31
US20130005689A1 (en) 2013-01-03
AP2013007282A0 (en) 2013-11-30
KR20140042884A (ko) 2014-04-07
IL230657B (en) 2018-02-28
MD4436B1 (ro) 2016-09-30
MX2013014938A (es) 2014-04-30
KR20160106207A (ko) 2016-09-09
MD20140009A2 (ro) 2014-06-30
ECSP13013087A (es) 2014-01-31
US9000015B2 (en) 2015-04-07
TW201307288A (zh) 2013-02-16
US20130203704A1 (en) 2013-08-08
HK1197236A1 (en) 2015-01-09
PL2726460T3 (pl) 2016-03-31
ES2656716T3 (es) 2018-02-28
NZ618537A (en) 2016-03-31
ZA201308977B (en) 2014-08-27
EP2993170B1 (en) 2017-10-25
EP2726460B1 (en) 2015-09-23
CR20130659A (es) 2014-02-18
SG10201605355RA (en) 2016-08-30
CA2840763A1 (en) 2013-01-10
SI2726460T1 (sl) 2015-11-30
PE20141067A1 (es) 2014-09-05
ES2553829T3 (es) 2015-12-14
IL230657A0 (en) 2014-03-31
EP2726460A1 (en) 2014-05-07
TWI567061B (zh) 2017-01-21
AU2012279332B2 (en) 2015-02-05
PT2726460E (pt) 2015-12-07
US10507215B2 (en) 2019-12-17

Similar Documents

Publication Publication Date Title
JP2014520809A (ja) 嗜癖の処置のための化合物
US7951813B2 (en) Quinazolinone derivatives as ALDH-2 inhibitors
US20200237789A1 (en) Combination therapy for preventing addiction
TWI468403B (zh) 用於治療成癮之ａｌｄｈ－２抑制劑
US20210145844A1 (en) Combination therapy for nicotine addiction
HK1217487B (en) N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives as aldh-2 inhibitors for the treatment of addiction
NZ618537B2 (en) Mitochondrial aldehyde dehydrogenase (ALDH-2) inhibitors
AU2015202264A1 (en) Compounds for the treatment of addiction
AU2016244324A1 (en) Compounds for the treatment of addiction
OA16801A (en) Compounds for the treatment of addiction.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160506

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160524

R150 Certificate of patent or registration of utility model

Ref document number: 5943998

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees